RxDoctor Payments Data

Kristina Campton, MD

Dermatology · New York, NYNPI 1902832777

Payments from drug & device makers

$34,584in general payments, 2019–2025

Across 693 payments — averaging $49.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Pfizer$7K
  • Incyte Corporation$4K
  • UCB, Inc.$872
  • Sun Pharmaceutical Industries Inc.$774
  • Johnson & Johnson$762
  • plus $4K from 24 others

What the payments were for

  • Consulting fees$3,97719%
  • Speaking & faculty fees$5,04024%
  • Travel & lodging$8404%
  • Food & beverage$11,29053%
  • Education$2001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,584 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$51,716
Medicare patients
203
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate557$1,085,410
RinvoqUpadacitinib94$626,123
Humira(Cf) PenAdalimumab21$247,746
NuzyraOmadacycline Tosylate16$121,527
LitfuloRitlecitinib Tosylate11$43,202
VtamaTapinarof27$36,986
Clobetasol Propionate318$19,585
WinleviClascoterone22$12,345
Triamcinolone Acetonide271$5,205
Tretinoin61$4,755
Halobetasol Propionate48$3,623
Ketoconazole152$2,547
Betamethasone Dipropionate56$2,435
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc35$2,341
Finasteride227$2,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$3,512$1,085,410557 claims
AbbVieRinvoq$17,463$626,12394 claims
Paratek Pharmaceuticals, Inc.Nuzyra$300$121,52716 claims
PfizerLitfulo$6,846$43,20211 claims
Dermavant Sciences, Inc.Vtama$512$36,98627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →